Real Life Data on OnabotulinumtoxinA for Treatment of Chronic Migraine in Pediatric Age

Background: The use of OnabotulinumtoxinA (OBT-A) for the treatment of chronic migraine (CM) in adults represents a therapy with the greatest efficacy and safety data. However, we have little evidence on the use of OBT-A in children or adolescents. The present study aims to describe the experience with OBT-A in the treatment of CM in adolescents in an Italian third-level headache center. Methods: The analysis included all patients under the age of 18 treated with OBT-A for CM at the Bambino Gesu Children's Hospital. All patients received OBT-A following the PREEMPT protocol. Subjects were classified as good responders if a greater than 50% reduction in the monthly frequency of attacks was observed, partial responders if the reduction was between 30 and 50%, and non-responders if it was <30%. Results: The treated population consisted of 37 females and 9 males with a mean age of 14.7 years. Before starting OBT-A, 58.7% of the subjects had attempted prophylactic therapy with other drugs. From OBT-A initiation to the last clinical observation, the mean duration of follow-up was 17.6 +/- 13.7 SD (range: 1-48) months. The number of OBT-A injections were 3.4 +/- 3 SD. Sixty eight percent of the subjects responded to treatment within the first three administrations of OBT-A. Proceeding with the number of administrations, a progressive improvement in frequency was further observed. Conclusions: The use of OBT-A in pediatric age can have benefits in terms of reduction in the frequency and intensity of headache episodes. Furthermore, treatment with OBT-A has an excellent safety profile. These data support the use of OBT-A in the treatment of childhood migraine.

Automated summary

This study aims to describe the experience with the use of OnabotulinumtoxinA (OBT-A) in the treatment of chronic migraine in adolescents. The results show that OBT-A can reduce the frequency and intensity of headache episodes and has a good safety profile. These data support the use of OBT-A in the treatment of childhood migraine.